Moleculin Biotech Inc (MBRX)

[king oil]

I think the headline caused the early jump in stock price but after the news was digested investors might perceive the results as mixed.

There are only 4 patients in each of the 2 studies. Most had no adverse effects however 1 patient did experience an issue. It wasn’t clear (at least to me) if that patient needed to drop out or could continue treatment.

The only example of improvement in condition that I could see in the press release was the 1 patient who had a partial response that could be used as a bridge to bone marrow transplant. The company seems to be saying that higher doses are needed in the US study to generate more improvement in those patients. In Poland there are 2 patients with results expected in Q2.

So overall good results but arguably not as strong as many might have been hoping to see.

Anyone else have an opinion on the results?